Edward Lebovics, M.D.
Professor of Medicine
Department of Medicine
Munger Pavilion-Suite 206
New York Medical College
Valhalla, NY 10595
Edward Lebovics is the Sarah C. Upham Professor of Gastroenterology.
Dr. Lebovics currently serves as the Director of the College’s Sarah C. Upham Division of Gastroenterology and Hepatobiliary Diseases. He is Chief of the Section of Gastroenterology and Hepatobiliary Diseases at Westchester Medical Center, which has become a leading liver transplant center. He has directed the College’s gastroenterology fellowship training program since 1997. Dr. Lebovics also serves on the Medical Advisory Boards of the New York Chapters of the American Liver Foundation and Crohn’s and Colitis Foundation of America.
Dr. Lebovics’ clinical expertise and research have made significant contributions in the fields of gastrointestinal and liver disease. His special interests include advanced therapeutic endoscopy, hepatitis C virus infection, chronic liver diseases, and inflammatory bowel disease. He has authored numerous articles and book chapters and delivered many invited lectures.
His achievements have been recognized by a Certificate of Special Congressional Recognition and by election to Fellowship at the American College of Physicians, American College of Gastroenterology and American Gastroenterological Association. He has been frequently listed amongst “Top Doctors” by New York Magazine and various other publications. Medical students and residents have also recognized his commitment to teaching through Excellence in Teaching Awards.
Post Graduate Studies:
Graduate Degree: M.D.
Graduate Degree Institution: New York University School of Medicine
Undergraduate Institution: Yeshiva University
Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev 2011;27:419-24.
Thadani A, Harley J, Rubin J, Lebovics E. Clinical significance of discordant hepatitis C virus transcription mediated amplification result following end of therapy response. Dig Dis Sci, 2011; in press
Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate Mofetil for Autoimmune Hepatitis: A Single Practice Experience. Dig Dis Sci. 2009; 54(11):2519-22.
Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E., Min AD, Bodenheimer HC Jr., Esposito SP, Brown RS Jr., Brau N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D. Edlin BR. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. Nov 2005; 100(11):2453-62.
Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, Related Article Bach N, Klion F, Tobias H, Antignano L, Brown RS Jr, Gabbaizadeh D. Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol. 2004 Sep;99(9):1700-5.
Rigas B, Hasan I, Rehman R, Donahue P, Wittkowski KM, Lebovics E. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet December 8, 2001;358(9297):1961-2.
Min AD, Jones JL, Esposito S, Lebovics E, Jacobson IM, Klion FM, Goldman IS, Geders JM, Tobias H, Bodian C, Bodenheimer HC Jr. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gastroenterol. 2001 Apr;96(4):1143-9.
Lebovics E, Seif F, Kim D, Elhosseiny A, Dworkin BM, Casellas A, Clark S, Rosenthal WS. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci.1997 May; 42(5):1094-9.
Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS. The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management and outcome. Am J Gastroenterol 1995 Jun;90(6):951-4